BioSpace News Archive

Engineered knockout cell lysates for reproducible proteomic analysis

Abcam’s new engineered knockout cell lysates enable proteomic studies by providing researchers with “true negative” controls.

November 10, 2019
·
2 min read
Business

SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to develop next-generation antibody-drug conjugates

NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate under their existing license and collaboration agreement.

November 10, 2019
·
4 min read
Zelluna Immunotherapy presents data on its lead compound ZI-H04 at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Zelluna Immunotherapy, a biopharma company developing T-cell receptor guided adoptive cell therapy products for treatment of multiple solid cancers, announces it will present data on its lead TCR compound, ZI-H04 at a poster session.

November 10, 2019
·
1 min read
Business

InflaRx Reports Third Quarter 2019 Financial & Operating Results

Recently announced results of open label extension part of SHINE Phase IIb study confirm potential of IFX-1 in Hidradenitis Suppurativa and warrant evaluation of future development

November 10, 2019
·
9 min read
Pharm Country

Industry Leaders Convene in New York for EXTRA: TrialScope Transparency Experience

TrialScope Announces Winners of 2nd Annual Clārus Awards

November 10, 2019
·
2 min read
UKI2S wins Best Sector Support Organisation at the OBN Awards

UK Innovation & Science Seed Fund is delighted to announce it is has been awarded ‘Best Sector Support Organisation’ at the 11th Annual OBN Awards celebration last night.

November 10, 2019
·
3 min read
Business

Enterome enters research collaboration with major cancer center focused on new microbiome-derived immunotherapies

Collaboration aims to evaluate the potential of microbiome-derived antigens that mimic tumor antigens and neoantigens (“onco-mimics”) to induce anti-tumor immune responses

November 10, 2019
·
4 min read
Pharmamar S.A About Pharmamar Patients YONDELIS® Science & Innovation Shareholders and Investors Newsroom Careers

Genedata Selector® deployed to streamline complex cell line development processes

November 10, 2019
·
3 min read
Policy

Bridge Therapeutics Announces It Will Seek FDA Approval for BT-219, a Treatment for Opioid Dependence in the Coming Months

Bridge Therapeutics Inc. announced that it has received feedback from the Food and Drug Administration from a Pre-Investigational New Drug meeting for the development of BT-219, a therapy to treat Opioid Dependence.

November 10, 2019
·
2 min read
Drug Development

Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial

A clinical Phase II safety and efficacy trial is planned for 2020 for the treatment of influenza, an indication with a very high unmet medical need

November 10, 2019
·
5 min read